Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Collaboration revenue:
Collaboration revenue from customers	[1]	$ 0	$ 35,141
Total collaboration revenue		0	35,141
Operating expenses:
Research and development	[2]	107,016	128,816
General and administrative		25,236	27,140
Total operating expenses		132,252	155,956
Gain from divestiture of small molecule programs		14,537	0
Loss from operations		(117,715)	(120,815)
Interest and other income, net		15,913	11,034
Net loss		(101,802)	(109,781)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax		(1,939)	4,369
Comprehensive loss		$ (103,741)	$ (105,412)
Net loss per share, basic (usd per share)		$ (0.68)	$ (0.80)
Net loss per share, diluted (usd per share)		$ (0.68)	$ (0.80)
Weighted average number of shares outstanding, basic (in shares)		149,404,188	136,524,528
Weighted average number of shares outstanding, diluted (in shares)		149,404,188	136,524,528

[1] Includes related-party collaboration revenue from customers of $0.1 million for the three months ended March 31, 2023.

[2] Includes expenses for cost sharing payments due to a related party of $4.2 million for the three months ended March 31, 2023.